Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Next Previous
Trial Profile

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLR 121125 (Primary) ; Iopofosine I 131 (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Cellectar Biosciences

Most Recent Events

  • 14 May 2026 According to Cellectar Biosciences media release, The Company anticipates activating additional study sites throughout the second quarter and will provide dosimetry, safety and efficacy updates in the second quarter and throughout the balance of 2026.
  • 14 May 2026 According to Cellectar Biosciences media release, Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy Data Expected Mid-year 2026
  • 14 Apr 2026 According to Cellectar Biosciences media release, the first patient has been enrolled in this trial. Additional study sites being activated in Q2, plan to provide dosimetry, safety, and efficacy updates throughout 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top